Arnaud Beduneau

Prof. Arnaud Beduneau


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Toxicology
Verified
Journal Article
Closed access
RCRaphaël Cornu
Raphaël Cornu
ABArnaud Beduneau
Arnaud Beduneau
HMhelene MARTIN
helene MARTIN

11 March 2020 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
RCRaphaël Cornu
Raphaël Cornu
CCClaire Chrétien
Claire Chrétien
YPYann Pellequer
Yann Pellequer
HMHélène Martin
Hélène Martin
ABArnaud Beduneau
Arnaud Beduneau

29 October 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HJHenusha Jhundoo
Henusha Jhundoo
TSTobias Siefen
Tobias Siefen
ALAlfred Liang
Alfred Liang
CSChristoph Schmidt
Christoph Schmidt
JLJohn Lokhnauth
John Lokhnauth
Alf LamprechtAlf Lamprecht
Alf Lamprecht
Chitosan is used in various drug delivery approaches as a pharmaceutical excipient. Although its potential as an immunomodulatory agent has been reported, its use in this capacity has not been fully explored. The efficacy of chitosan as an active pharmacological agent, particularly in anti-inflammatory therapy in inflammatory bowel diseases (IBD), was investigated in this study. The potential impact of the molecular weight (MW) and degree of deacetylation (DD) of chitosan was investigated together with 5-amino salicylic acid (5-ASA) for its efficacy in a combination anti-inflammatory therapy in murine experimental colitis. Such a combination would potentially be developed into novel dual strategies whereby chitosan acts as a mucoadhesive excipient as well as provide an additional anti-inflammatory benefit. Chitosan grades with different MW and DD were administered intrarectally alone or in combination with 5-ASA to colitis mice for 3 days. Myeloperoxidase (MPO) and alkaline phosphatase (ALP) activity and tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) and nuclear factor kappa-B (NF-κB) levels were assessed from the colon. Intrarectal treatment of colitis with 30 mg/kg chitosan alone and with 30 mg/kg 5-ASA for 3 days led to a significant decrease in MPO, ALP, TNF-α, IL-6, IL-1β and NF-κB in colitis mice compared to untreated mice. Surprisingly, the efficacy of chitosan as an anti-inflammatory polymer was relatively independent from its structural properties, namely DD and MW. However, combinations of chitosan with 5-ASA showed a significant pharmacological improvement, whereby the additive anti-inflammatory efficacy observed shows the possibility of finetuning chitosan by combining it with anti-inflammatory agents to optimize its anti-inflammatory potential.

1 October 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MAMona MA Abdel-Mottaleb
Mona MA Abdel-Mottaleb
ABArnaud Beduneau
Arnaud Beduneau
YPYann Pellequer
Yann Pellequer
ALAlf Lamprecht
Alf Lamprecht

1 March 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DADelphine Antoine
Delphine Antoine
YPYann Pellequer
Yann Pellequer
CTCamille Tempesta
Camille Tempesta
SLStefan Lorscheidt
Stefan Lorscheidt
BKBernadette Kettel
Bernadette Kettel
ABArnaud Beduneau
Arnaud Beduneau

27 July 2022 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
RCRaphaël Cornu
Raphaël Cornu
ABArnaud Beduneau
Arnaud Beduneau
HMhelene MARTIN
helene MARTIN